Could a drug help AML patients fight Chemo-Related anemia?
NCT ID NCT07663864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find the best timing for the drug and assess its effectiveness in reducing severe anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- luspatercept
- What this could lead to
- If it works, this could offer a new way to manage chemotherapy-induced anemia in AML patients, reducing the need for blood transfusions.
- What could go wrong
- This is an early-phase, single-arm study with only 40 participants, so results may not be generalizable. The drug may not effectively raise hemoglobin or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCING ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, Guangdong Second Provincial General Hospital
RECRUITINGGuangzhou, Guangdong, China